Evaluating the HIV cellular reservoir in preclinical and Phase 1 clinical trial samples after latency reversal with activator vaccines.

使用激活疫苗逆转潜伏期后，评估临床前和一期临床试验样本中的 HIV 细胞库。

• 批准号: 351865
• 负责人: Mann Jamie F
• 金额: $ 7.29万
• 依托单位: University of Western Ontario
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2016
• 资助国家: 加拿大
• 起止时间: 2016-04-01 至 2017-04-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=351865&lang=en
• 关键词: Cd4 T Cells; Ctl; Hiv; Latency; Rna; Sequencing; Virus Like Particles

The inability to reactivate the HIV latent reservoir within HIV-specific CD4 T cells, the major cell reservoir for HIV, constitutes a significant roadblock for an HIV cure. Recent advances in latency reversal agents have shown transcriptional reactivation

无法重新激活HIV特异性CD4 T细胞（HIV的主要细胞库）内的HIV潜伏库，构成了HIV治愈的重大障碍。潜伏逆转药物的最新进展显示转录再激活